Robertson 1985.

Study characteristics
Methods	A single‐centre, randomised, double‐blind, controlled trial (UK) Baseline period: unclear Treatment period: 12 weeks (6 weeks for all 3 arms of trial, then 6 weeks for the 2 antidepressants only)
Participants	42 people with epilepsy exceeding 15 points on the HAMD‐21 scale for depression 26 females and 13 males Aged 18 to 60 years
Interventions	Amitriptyline (N = 14) 25 mg TDS Nomifensine (N = 14) 25mg TDS Placebo (N = 14)
Outcomes	1) Improvement in depressive symptoms 2) Seizure frequency 3) Adverse effects
Notes	39 people included in the analysis. At 6 weeks, non‐responders in the active drug arms had dose doubled, and those in the placebo arm were withdrawn from the study
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number codes used, however generation of this randomisation sequence is unclear
Allocation concealment (selection bias)	Low risk	Pharmacy‐controlled allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study personnel and participants blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessor blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Missing data detected and attrition reported
Selective reporting (reporting bias)	Low risk	Outcomes stated in methods section of report are present in the results. No protocol available
Other bias	Unclear risk	After 6 weeks, placebo group removed from trial; only active antidepressant treatment groups continued in the trial